I'm now keeping an eye on: The SmPC for Tyenne 20 mg/mL concentrate for solution for infusion
🏭Fresenius Kabi Ltd
💊💉 #tocilizumab.
I will let you know if it changes.
🌐 https://www.medicines.org.uk/emc/product/15244/smpc
Tyenne 20 mg/mL concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (emc)
Tyenne 20 mg/mL concentrate for solution for infusion - Summary of Product Characteristics (SmPC) by Fresenius Kabi Ltd
I'm now keeping an eye on: The SmPC for Tyenne 162 mg solution for injection in pre-filled syringe
🏭Fresenius Kabi Ltd
💊💉 #tocilizumab.
I will let you know if it changes.
🌐 https://www.medicines.org.uk/emc/product/15243/smpc
Tyenne 162 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC) - (emc)
Tyenne 162 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC) by Fresenius Kabi Ltd
I'm now keeping an eye on: The SmPC for Tyenne 162 mg solution for injection in pre-filled pen
🏭Fresenius Kabi Ltd
💊💉 #tocilizumab.
I will let you know if it changes.
🌐 https://www.medicines.org.uk/emc/product/15242/smpc
Tyenne 162 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC) - (emc)
Tyenne 162 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC) by Fresenius Kabi Ltd
May have shared this before. Some evidence of IL-6 hyperinflammation in people living with #HIV
#tocilizumab #IDMastodon #infectiousdiseases #microbiology #medicine
Interleukin 6 Blockade With Tocilizumab Diminishes Indices of Inflammation That Are Linked to Mortality in Treated Human Immunodeficiency Virus Infection https://academic.oup.com/cid/article/77/2/272/7100622?login=true

Interleukin 6 Blockade With Tocilizumab Diminishes Indices of Inflammation That Are Linked to Mortality in Treated Human Immunodeficiency Virus Infection
Inhibition of IL-6 activity by tocilizumab had profound effects on immune activation/inflammation and lipid profiles in people with treated HIV infection.
OUP Academic
His Rare Disease's Cure Was Sitting on the Pharmacy Shelf
He's alive thanks to a repurposed drug. Now his dream is to find cures for millions of people from among drugs we already have.
MedscapeTocilizumab-induced Hypofibrinogenemia in SJIA Patients - Not Standing Stills Disease
According to a study in Nature, tocilizumab can cause hypofibrinogenemia in SJIA patients. Here's what you should know.
Not Standing Stills Disease1/
Our summary of #TargetTrial emulation is out.
We illustrate it with another observational success:
A survival benefit of #tocilizumab in critically ill #COVID19 patients was quantified using observational data before a randomized trial confirmed it.
👇
https://jamanetwork.com/journals/jama/fullarticle/2799678

Target Trial Emulation for Causal Inference From Observational Data
This Guide to Statistics and Methods describes the use of target trial emulation to design an observational study so it preserves the advantages of a randomized clinical trial, points out the limitations of the method, and provides an example of its use.

Brevetti e pillole amare: l'Ue continua a difendere Big Pharma, non solo sui vaccini
Dopo aver negato ai Paesi a basso reddito un accesso equo ai vaccini, l’Unione europea è pronta a fare lo stesso con i medicinali per il trattamento del Covid-19, privilegiando gli interessi di Pfizer, Merck, Roche, AstraZeneca e GSK e tagliando fuori milioni di persone. La denuncia del Corporate europe observatory
AltreconomiaImpfungen gegen COVID-19 dominieren die Schlagzeilen. Bei Medikamenten kommen Ärzte und Forscher eher schleppend voran. Hier ein Überblick über den derzeit gültigen Stand der Therapie.
Jenseits der Impfung: Kommt das Medikament gegen COVID-19 noch? | DW | 25.08.2021
Jenseits der Impfung: Kommt das Medikament gegen COVID-19 noch? | DW | 25.08.2021
Impfungen gegen COVID-19 dominieren die Schlagzeilen. Bei Medikamenten kommen Ärzte und Forscher eher schleppend voran. Hier ein Überblick über den derzeit gültigen Stand der Therapie.
Impfungen gegen COVID-19 dominieren die Schlagzeilen. Bei Medikamenten kommen Ärzte und Forscher eher schleppend voran. Hier ein Überblick über den derzeit gültigen Stand der Therapie.
Jenseits der Impfung: Kommt das Medikament gegen COVID-19 noch? | DW | 25.08.2021#Impfung #Medikamente #Intensivstation #COVID-19 #Coronavirus #Intensivmedizin #Dexamethason #Tocilizumab
Jenseits der Impfung: Kommt das Medikament gegen COVID-19 noch? | DW | 25.08.2021
Impfungen gegen COVID-19 dominieren die Schlagzeilen. Bei Medikamenten kommen Ärzte und Forscher eher schleppend voran. Hier ein Überblick über den derzeit gültigen Stand der Therapie.